Status:
SUSPENDED
Prevalence and Impact on QoL From Ototoxicity in Cancer Survivors
Lead Sponsor:
University of Nottingham
Collaborating Sponsors:
National Institute for Health Research, United Kingdom
International Stem Cell Forum
Conditions:
Hearing Loss, Sensorineural
Tinnitus, Subjective
Eligibility:
All Genders
18+ years
Brief Summary
This study will involve collaborating with oncologists in the post-chemotherapy follow-up appointments. The participants who wish to consent to this study will then answer 3 short questionnaires (THI,...
Detailed Description
There has been a substantial increase in cancer survival rates in the the past decades, however many cancer survivors are now impacted by the multitude of toxicities associated with treatment. It is o...
Eligibility Criteria
Inclusion
- Ability to give informed consent
- Age 18+ at time of cancer diagnosis
- At least 1 cycle of any type of platinum-based chemotherapy
- 0-5 years following first cycle of platinum-based chemotherapy
- Comprehensive understanding of the English language
Exclusion
- Previous radiotherapy to the head and neck area
- Pre-existing hearing deficits
Key Trial Info
Start Date :
February 3 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2020
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04270916
Start Date
February 3 2020
End Date
September 1 2020
Last Update
March 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nottingham University Hospitals NHS trust
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB